Previous 10 | Next 10 |
CHARLOTTESVILLE, Va., June 27, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...
Adial Pharmaceuticals (NASDAQ:ADIL) said June 14 that the U.S. Patent and Trademark Office issued a patent on June 7 covering the use of its genetic diagnostic panel in combination with lead product AD04 to treat alcohol use disorder (AUD) and opioid use disorder (OUD). The company said the p...
CHARLOTTESVILLE, Va., June 14, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and ...
Gainers: Turning Point Therapeutics (TPTX) +116%. Amylyx Pharmaceuticals (AMLX) +27%. Yumanity Therapeutics (YMTX) +11%. Amarin (AMRN) +9%. Galecto (GLTO) +8%. Losers: Novavax (NVAX) -13%. Rallybio (RLYB) -13%. Invitae (NVTA) -9%. Spruce Bioscience...
CHARLOTTESVILLE, Va., May 19, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing novel molecules targeting the adenosine receptors...
Adial Pharmaceuticals press release (NASDAQ:ADIL): Q1 GAAP EPS of -$0.13 beats by $0.04. As of March 31, 2022, cash and cash equivalents were $12.7 million as compared to $6.1 million as of December 31, 2021. For further details see: Adial Pharmaceuticals GAAP EPS of -$0.13 beats by $0....
Adial Pharmaceuticals press release (NASDAQ:ADIL): Q1 GAAP EPS of -$0.13 beats by $0.04. As of March 31, 2022, cash and cash equivalents were $12.7M vs. $6.1M as of Dec. 31, 2021. On track to report results from Onward phase 3 trial of AD04 for the treatment of alcohol use disorder in the cur...
Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter Ended first quarter with cash and cash equivalents of $12.7 million CHARLOTTESVILLE, Va., May 16, 2022 (GLOBE...
CHARLOTTESVILLE, Va., May 04, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., an Adial company focused on developing adenosine analogs for the treatment of major unme...
CHARLOTTESVILLE, Va., March 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and...
News, Short Squeeze, Breakout and More Instantly...
Adial Pharmaceuticals Inc Company Name:
ADIL Stock Symbol:
NASDAQ Market:
Adial Pharmaceuticals Inc Website:
GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,...
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Today the MicroCap Rodeo - Spring into Summer will take place in-person on Thursday, June 6th, 2024 and host the executive management teams of 25 microcap companies. The conference will be held live at Convene NYC, with company presentations from begin...